Life sciences firm Biogen Idec has announced the appointment of Michael E.
Life sciences firm Biogen Idec has announced the appointment of Michael E. Lytton as executive vice-president for business and corporate development, with responsibility for leading the company’s business development activities.
Since 2001 Lytton (pictured) has been a general partner at Oxford Bioscience Partners, a venture capital firm that provides equity financing and general management assistance to emerging life sciences companies.
At Oxford, Lytton led or co-led a dozen investments in a range of therapeutic areas, including central nervous system disorders, inflammatory diseases and oncology. He worked successfully with management and boards of portfolio companies to drive growth through restructurings, M&A and exits through sales to larger companies.
From 1993 to 2000 he was partner, chairman of the technology group, and a member of the executive committee of Palmer & Dodge, a Boston-based law firm (now Edwards Angell Palmer & Dodge). While there, he negotiated multiple M&A transactions, corporate partnerships and licensing deals.
‘Michael brings more than 25 years of business development, investment and legal experience in the biotechnology industry,’ says Biogen Idec chief operating officer Hans Peter Hasler. ‘His M&A background, as well as his experience in identifying and translating promising science into successful companies, makes him uniquely qualified to build on our track record of highly disciplined and productive business development.’
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs.
